Newell Joe 4
4 · Atara Biotherapeutics, Inc. · Filed Mar 15, 2021
Insider Transaction Report
Form 4
Newell Joe
Chief Tech. Operations Officer
Transactions
- Exercise/Conversion
Common Stock
2021-03-15$12.15/sh+3,500$42,525→ 145,219 total - Sale
Common Stock
2021-03-15$17.41/sh−7,000$121,870→ 138,219 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-03-15−2,791→ 43,250 totalExercise: $12.15Exp: 2030-02-28→ Common Stock (2,791 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-03-15−709→ 12,750 totalExercise: $12.15Exp: 2030-02-28→ Common Stock (709 underlying)
Footnotes (3)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020.
- [F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.01 to $17.59. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service.